Drugs / SIM0278
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06022354 | Aug 2023 → Mar 2025 | — | Jiangsu Simcere Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07175233 | Oct 2025 → Aug 2026 overdue | atopic eczema | Jiangsu Simcere Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-07-27 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Regulatory Sim0278 injection (il-2 mutant fc fusion protein) obtained clinical trial approval, exploring solutions to continuous medication disturbance for hundreds of millions of atopic dermatitis patients simcere.com ↗
SIM0278 approved for Phase I clinical study |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-11-10 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Simcere's IL-2 Mutant Fusion Protein SIM0278 Entered Phase II Clinical Trial Stage simcere.com ↗ |
| 2023-12-22 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Almirall initiated a phase I clinical study of SIM0278 (ALM223) simcere.com ↗ |
| 2023-08-26 | Jiangsu Simcere Pharmaceutical Co., Ltd. | The First Subject Dosed with SIM0278, an Innovative IL-2 mu-Fc Independently Developed by Simcere Pharmaceutical simcere.com ↗ |
| 2023-07-27 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Sim0278 injection (il-2 mutant fc fusion protein) obtained clinical trial approval, exploring solutions to continuous medication disturbance for hundreds of millions of atopic dermatitis patients simcere.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SIM0278 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06022354 ↗ |
| Route | Subcutaneous | “via subcutaneous injection” NCT06022354 ↗ |